Bone density recovery after depot medroxyprogesterone acetate injectable contraception use

Contraception

Volumn 77, Issue 2, 2008, Pages 67-76

  Kaunitz, Andrew M ^a   Arias, Raquel ^b   McClung, Michael ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Bone mineral density; Contraception; Depot medroxyprogesterone acetate; Injectable

Indexed keywords

LEUPRORELIN; MEDROXYPROGESTERONE ACETATE;

ADOLESCENCE; BONE DENSITY; CLINICAL STUDY; CLINICAL TRIAL; CONTRACEPTION; DRUG WITHDRAWAL; ENDOMETRIOSIS; FOLLOW UP; FRACTURE; HUMAN; MEDLINE; OBSERVATIONAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

BONE DENSITY; BONE RESORPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FRACTURES, BONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; RISK FACTORS; TIME FACTORS;

EID: 38349184212     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.10.005     Document Type: Review

References (83)

1. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety. Contraception 68 (2003) 75-87
2. Cromer B.A. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol 15 (2003) 353-357
3. Chiou C.F., Trussell J., Reyes E., et al. Economic analysis of contraceptives for women. Contraception 68 (2003) 3-10
4. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
5. Mosher W.D., Martinez G.M., Chandra A., Abma J.C., and Willson S.J. Use of contraception and use of family planning services in the United States: 1982-2002. Advance data from vital and health statistics; No. 350 (2004), National Center for Health Statistics, Hyattsville, MD
6. Shelton J. FDA Approval of SC Depo-Provera. Center for Communication Programs Pearl of the Week (2006), The Johns Hopkins University, Baltimore. http://www.jhuccp.org/pearls www.jhuccp.org/pearls. Accessed August 29
7. Jain J., Jakimiuk A.J., Bode F.R., Ross D., and Kaunitz A.M. Contraceptive efficacy and safety of DMPA-SC. Contraception 70 (2004) 269-275
8. Depo-Provera [physician information] (2004), Pfizer Inc, New York
9. Mishell Jr. D.R. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41 (1996) 381-390
10. Hergenroeder A.C. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 126 (1995) 683-689
11. Gbolade B.A. Depo-Provera and bone density. J Fam Plann Reprod Health Care 28 (2002) 7-11
12. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
13. Tang O.S., Tang G., Yip P., Li B., and Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception 59 (1999) 25-29
14. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
15. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
16. Scholes D., Lacroix A.Z., Ott S.M., Ichikawa L.E., and Barlow W.E. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 93 (1999) 233-238
17. Paiva L.C., Pinto-Neto A.M., and Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 58 (1998) 351-355
18. Lara-Torre E., Edwards C.P., Perlman S., and Hertweck S.P. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17 (2004) 17-21
19. Gbolade B., Ellis S., Murby B., Randall S., and Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 105 (1998) 790-794
20. Cromer B.A., Lazebnik R., Rome E., Bonny A., Ziegler J., and Debanne S.M. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 192 (2005) 42-47
21. Cromer B.A., Stager M., Bonny A., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35 (2004) 434-441
22. Cromer B.A., Blair J.M., Mahan J.D., Zibners L., and Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129 (1996) 671-676
23. Clark M.K., Sowers M.F.R., Nichols S., and Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 82 (2004) 1580-1586
24. Berenson A.B., Radecki C.M., Grady J.J., Rickert V.I., and Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 98 (2001) 576-582
25. Bahamondes L., Perrotti M., Castro S., Faundes D., Petta C., and Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 71 (1999) 849-852
26. Cundy T., Evans M., Roberts H., Wattie D., Ames R., and Reid I.R. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 303 (1991) 13-16
27. Cundy T., Cornish J., Roberts H., Elder H., and Reid I.R. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92 (1998) 569-573
28. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 186 (2002) 978-983
29. Cundy T., Ames R., Horne A., Roberts H., Gamble G., and Reid I.R. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 88 (2003) 78-81
30. Berenson A.B., Breitkopf C.R., Grady J.J., Rickert V.I., and Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103 (2004) 899-906
31. Kaunitz A.M., Miller P.D., Rice V.M., Ross D., and McClung M.R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74 (2006) 90-99
32. Naessen T., Olsson S.E., and Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52 (1995) 35-39
33. Tang O.S., Tang G., Yip P.S., and Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception 62 (2000) 161-164
34. Virutamasen P., Wangsuphachart S., Reinprayoon D., Kriengsinyot R., Leepipatpaiboon S., and Gua C. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia Oceania J Obstet Gynaecol 20 (1994) 269-274
35. Taneepanichskul S., Intaraprasert S., Theppisai U., and Chaturachinda K. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception 56 (1997) 1-3
36. Taneepanichskul S., Intaraprasert S., Theppisai U., and Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception 56 (1997) 153-155
37. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49 (1998) 615-618
38. Merki-Feld G.S., Neff M., and Keller P.J. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. BJOG 107 (2000) 863-869
39. Merki-Feld G.S., Neff M., and Keller P.J. A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users. Contraception 67 (2003) 79-86
40. Petitti D.B., Piaggio G., Mehta S., Cravioto M.C., and Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 95 (2000) 736-744
41. Busen N.H., Britt R.B., and Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 32 (2003) 257-259
42. Beksinska M.E., Smit J.A., Kleinschmidt I., Farley T.M., and Mbatha F. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception 71 (2005) 170-175
43. Scholes D., Lacroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 69 (2004) 99-104
44. Tharnprisarn W., and Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception 66 (2002) 101-103
45. Wanichsetakul P., Kamudhamas A., Watanaruangkovit P., Siripakarn Y., and Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 65 (2002) 407-410
46. Schlaff W.D., Carson S.A., Luciano A., Ross D., and Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 85 (2006) 314-325
47. Ryan P.J., Singh S.P., and Guillebaud J. Depot medroxyprogesterone and bone mineral density. J Fam Plann Reprod Health Care 28 (2002) 12-15
48. Rome E., Ziegler J., Secic M., et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol 17 (2004) 373-377
49. Perrotti M., Bahamondes L., Petta C., and Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 76 (2001) 469-473
50. Crosignani P.G., Luciano A., Ray A., and Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 21 (2006) 248-256
51. Shaarawy M., El Mallah S.Y., Seoudi S., Hassan M., and Mohsen I.A. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 74 (2006) 297-302
52. Clark M.K., Sowers M., Levy B., and Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril (2006)
53. Cundy T., Cornish J., Evans M.C., Roberts H., and Reid I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 308 (1994) 247-248
54. Albertazzi P., Bottazzi M., and Steel S.A. Bone mineral density and depot medroxyprogesterone acetate. Contraception 73 (2006) 577-583
55. Cundy T., Ames R., Clearwater J., et al. Bone density in long-term DMPA users: a double-blind randomised controlled trial of estrogen replacement therapy. J Bone Miner Res 16 (2001) S221 Abstract F390
56. World Health Organization. WHO Statement on Hormonal Contraception and Bone Health. WHO Epidemiological Record No. 35 (2005), World Health Organization, Geneva, Switzerland
57. McClung M.R. The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep 3 (2005) 57-63
58. Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 16 (2005) 581-589
59. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., and Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 (2001) 989-995
60. Black A. Canadian contraception consensus-update on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can 28 (2006) 305-313
61. Banks E., Berrington A., and Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 108 (2001) 1214-1221
62. Kalkwarf H.J., and Specker B.L. Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol 86 (1995) 26-32
63. Polatti F., Capuzzo E., Viazzo F., Colleoni R., and Klersy C. Bone mineral changes during and after lactation. Obstet Gynecol 94 (1999) 52-56
64. Karlsson C., Obrant K.J., and Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int 12 (2001) 828-834
65. Chantry C.J., Auinger P., and Byrd R.S. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 158 (2004) 650-656
66. Carranza-Lira S., and Mera J.P. Influence of number of pregnancies and total breast-feeding time on bone mineral density. Int J Fertil 47 (2002) 169-171
67. Prentice A., Jarjou L.M., Cole T.J., Stirling D.M., Dibba B., and Fairweather-Tait S. Calcium requirements of lactating Gambian mothers: effects of a calcium supplement on breast-milk calcium concentration, maternal bone mineral content, and urinary calcium excretion. Am J Clin Nutr 62 (1995) 58-67
68. Ritchie L.D., Fung E.B., Halloran B.P., et al. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 67 (1998) 693-701
69. Krebs N.F., Reidinger C.J., Robertson A.D., and Brenner M. Bone mineral density changes during lactation: maternal, dietary, and biochemical correlates. Am J Clin Nutr 65 (1997) 1738-1746
70. Lopez J.M., Gonzalez G., Reyes V., Campino C., and Diaz S. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos Int 6 (1996) 153-159
71. Sowers M., Corton G., Shapiro B., et al. Changes in bone density with lactation. JAMA 269 (1993) 3130-3135
72. Paton L.M., Alexander J.L., Nowson C.A., Frame M.G., Kaymakci B., and Wark J.D. Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study. Am J Clin Nutr 77 (2003) 707-714
73. Henderson III P.H., Sowers M.F., Kutzko K.E., and Jannausch M.L. Bone mineral density in grand multiparous women with extended lactation. Am J Obstet Gynecol 182 (2000) 1371-1377
74. Kolthoff N., Eiken P., Kristensen B., and Nielsen S.P. Bone mineral changes during pregnancy and lactation: a longitudinal cohort study. Clin Sci (Lond) 94 (1998) 405-412
75. Hayslip C.C., Klein T.A., Wray H.L., and Duncan W.E. The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 73 (1989) 588-592
76. More C., Bettembuk P., Bhattoa H.P., and Balogh A. The effects of pregnancy and lactation on bone mineral density. Osteoporos Int 12 (2001) 732-737
77. Holmberg-Marttila D., and Sievanen H. Prevalence of bone mineral changes during postpartum amenorrhea and after resumption of menstruation. Am J Obstet Gynecol 180 (1999) 537-538
78. Kalkwarf H.J. Lactation and maternal bone health. Adv Exp Med Biol 554 (2004) 101-114
79. Honda A., Kurabayashi T., Yahata T., Tomita M., Takakuwa K., and Tanaka K. Lumbar bone mineral density changes during pregnancy and lactation. Int J Gynecol Obstet 63 (1998) 253-258
80. Hillier T.A., Rizzo J.H., Pedula K.L., et al. Nulliparity and fracture risk in older women: the study of osteoporotic fractures. J Bone Miner Res 18 (2003) 893-899
81. Michaelsson K., Baron J.A., Farahmand B.Y., and Ljunghall S. Influence of parity and lactation on hip fracture risk. Am J Epidemiol 153 (2001) 1166-1172
82. Cromer B.A., Scholes D., Berenson A., Cundy T., Clark M.K., and Kaunitz A.M. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 39 (2006) 296-301
83. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107 (2006) 1453-1472